7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Objective

          The aim of our investigation was to evaluate the clinicopathological characteristics and mutation patterns in newly diagnosed cases of thyroid cancer in the federal state of Salzburg, Austria, in the year 2013.

          Methods

          The medical records of all patients newly diagnosed with thyroid cancer in 2013 in the federal state of Salzburg were retrospectively reviewed. The clinicopathological characteristics and mutations of thyroid cancers were analyzed.

          Results

          63 patients (mean age: 51.0 years, range: 21–81 years; female 75%, male 25%) were identified. 53 patients had papillary (12 follicular variant), 4 patients follicular (1 oxyphilic variant), 3 patients medullary, and 3 patients anaplastic thyroid cancer. T1 tumors were found in 34 patients (pT1a, 20 patients; pT1b, 14 patients), T2 tumors in 10 patients, T3 tumors in 16 patients, and T4 tumors in 3 patients. Lymph node involvement was seen in 15 patients and metastatic disease in 1 patient. Mutations of BRAF (B-type Raf kinase) were detected in 23 and mutation of NRAS (Neuroblastoma RAS Viral Oncogene Homolog) in 2 papillary thyroid cancers. No concomitant mutations of BRAF and NRAS were found.

          Conclusion

          Females accounted for 75% of the patients with newly diagnosed thyroid cancer and the incidence peaked at a younger age than in males. Papillary thyroid cancer was the most frequent tumor type, accounting for 84% of the cases. A high frequency of T1 tumors and cancers with no lymph node involvement was found. Males had a higher proportion of large tumors and more aggressive forms of thyroid cancer than females. Mutations (mostly of BRAF) were found in 47% of the cases. Neither mutations of KRAS (Kirsten rat sarcoma viral oncogene homologue) nor concomitant mutations of BRAF and NRAS were found.

          Related collections

          Most cited references22

          • Record: found
          • Abstract: found
          • Article: not found

          High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

          Thyroid papillary cancers (PTCs) are associated with activating mutations of genes coding for RET or TRK tyrosine kinase receptors, as well as of RAS genes. Activating mutations of BRAF were reported recently in most melanomas and a small proportion of colorectal tumors. Here we show that a somatic mutation of BRAF, V599E, is the most common genetic change in PTCs (28 of 78; 35.8%). BRAF(V599E) mutations were unique to PTCs, and not found in any of the other types of differentiated follicular neoplasms arising from the same cell type (0 of 46). Moreover, there was no overlap between PTC with RET/PTC, BRAF, or RAS mutations, which altogether were present in 66% of cases. The lack of concordance for these mutations was highly unlikely to be a chance occurrence. Because these signaling proteins function along the same pathway in thyroid cells, this represents a unique paradigm of human tumorigenesis through mutation of three signaling effectors lying in tandem.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            International patterns and trends in thyroid cancer incidence, 1973-2002.

            During the past several decades, an increasing incidence of thyroid cancer has been reported in many parts of the world. To date, no study has compared the trends in thyroid cancer incidence across continents. We examined incidence data from cancer incidence in five continents (CI5) over the 30-year period 1973-2002 from 19 populations in the Americas, Asia, Europe, and Oceania. Thyroid cancer rates have increased from 1973-1977 to 1998-2002 for most of the populations except Sweden, in which the incidence rates decreased about 18% for both males and females. The average increase was 48.0% among males and 66.7% among females. More recently, the age-adjusted international thyroid cancer incidence rates from 1998 to 2002 varied 5-fold for males and nearly 10-fold for females by geographic region. Considerable variation in thyroid cancer incidence was present for every continent but Africa, in which the incidence rates were generally low. Our analysis of published CI5 data suggests that thyroid cancer rates increased between 1973 and 2002 in most populations worldwide, and that the increase does not appear to be restricted to a particular region of the world or by the underlying rates of thyroid cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The changing epidemiology of thyroid cancer: why is incidence increasing?

              Thyroid cancer incidence is increasing worldwide. Causes are highly debated.
                Bookmark

                Author and article information

                Contributors
                +43-662-44823500 , +43-662-44823511 , c.pirich@salk.at
                Journal
                Wien Klin Wochenschr
                Wien. Klin. Wochenschr
                Wiener Klinische Wochenschrift
                Springer Vienna (Vienna )
                0043-5325
                1613-7671
                10 May 2017
                10 May 2017
                2017
                : 129
                : 15
                : 540-544
                Affiliations
                [1 ]ISNI 0000 0004 0523 5263, GRID grid.21604.31, Department of Nuclear Medicine and Endocrinology, , Paracelsus Medical University Salzburg, ; Müllner Hauptstrasse 48, 5020 Salzburg, Austria
                [2 ]Department of Nuclear Medicine, Schwarzach Hospital, Schwarzach, Austria
                [3 ]Department of Pathology, Schwarzach Hospital, Schwarzach, Austria
                [4 ]ISNI 0000 0004 0523 5263, GRID grid.21604.31, Department of Pathology, , Paracelsus Medical University Salzburg, ; Salzburg, Austria
                Author information
                http://orcid.org/0000-0002-0956-5935
                Article
                1207
                10.1007/s00508-017-1207-x
                5552837
                28493027
                70bdcc62-0113-4c4d-9fc4-cec8810ed6a0
                © The Author(s) 2017

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 24 March 2016
                : 12 April 2017
                Funding
                Funded by: University of Innsbruck and Medical University of Innsbruck
                Categories
                Original Article
                Custom metadata
                © Springer-Verlag GmbH Austria 2017

                Medicine
                thyroid cancer,endocrine system,diagnosis,gene mutation,fine-needle aspiration biopsy
                Medicine
                thyroid cancer, endocrine system, diagnosis, gene mutation, fine-needle aspiration biopsy

                Comments

                Comment on this article